Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2024-03-10 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Phase 1 onCARlytics Trial Advances to Combination Arm 3 pages 212.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 11 March 2024, describing the advancement of a Phase 1 clinical trial (OASIS trial) for their onCARlytics solid tumour treatment. It provides details about the trial design, patient cohorts, and the combination arm initiation. The document is a news release or update about clinical trial progress rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or governance information. It is also not a report publication announcement or certification. The content is primarily an operational update on clinical trial progress, which fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (5675 characters) and content support this classification with high confidence.
2024-03-10 English
Half Yearly Report and Accounts 32 pages 1.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'IMUGENE LIMITED APPENDIX 4D Half-year ended 31 December 2023' and contains detailed financial results, operational review, clinical trial updates, and financial statements for the half-year period ending 31 December 2023. It includes comprehensive financial data such as revenue, net loss, net tangible assets, and cash reserves, as well as detailed narrative on business activities and clinical progress. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of financial statements and a detailed review of operations aligns with the characteristics of an Interim / Quarterly Report. The Appendix 4D is a regulatory filing in Australia for half-year financial reports, which corresponds to an Interim Report (IR) in our classification. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2024-02-28 English
Phase 1 onCARlytics Trial Doses First Intravenous Patient 3 pages 211.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 February 2024 from Imugene Limited about dosing the first patient in a Phase 1 clinical trial for their onCARlytics drug candidate. It describes the trial design, patient recruitment, and clinical milestones. There are no financial statements, earnings data, or detailed financial analysis. The content focuses on clinical trial progress and company updates rather than financial results or regulatory filings. The document is relatively short (5279 characters) and reads as a corporate announcement about a clinical trial milestone. This fits best with a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other categories. It is not an earnings release, annual report, or investor presentation, nor does it relate to capital changes, management changes, or legal proceedings. Therefore, the appropriate classification is RNS with high confidence.
2024-02-14 English
Notice of change of interests of substantial holder - PH 4 pages 232.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a Notice of change of interests of a substantial holder. It details changes in voting power and shareholdings of Paul Hopper and associates in Imugene Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2024-02-01 English
Application for quotation of securities - IMU 8 pages 31.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX by Imugene Limited. It details the number and type of securities to be quoted, issue dates, escrow periods, and references to shareholder approval at an Extraordinary General Meeting. The content focuses on the issuance and quotation of shares, including details about the securities and compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is not a report but an announcement related to capital changes, specifically the quotation of new securities. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a confident classification.
2024-01-31 English
Application for quotation of securities - IMU 8 pages 30.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and classifications of securities. This type of document is related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, nor is it a regulatory announcement about voting or board changes. The document fits the category of Share Issue/Capital Change as it announces new securities being quoted following conversion of options.
2024-01-31 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.